Thyroid carcinoma, version 2.2014.
- Tuttle, R Michael;
- Haddad, Robert I;
- Ball, Douglas W;
- Byrd, David;
- Dickson, Paxton;
- Duh, Quan-Yang;
- Ehya, Hormoz;
- Haymart, Megan;
- Hoh, Carl;
- Hunt, Jason P;
- Iagaru, Andrei;
- Kandeel, Fouad;
- Kopp, Peter;
- Lamonica, Dominick M;
- Lydiatt, William M;
- McCaffrey, Judith;
- Moley, Jeffrey F;
- Parks, Lee;
- Raeburn, Christopher D;
- Ridge, John A;
- Ringel, Matthew D;
- Scheri, Randall P;
- Shah, Jatin P;
- Sherman, Steven I;
- Sturgeon, Cord;
- Waguespack, Steven G;
- Wang, Thomas N;
- Wirth, Lori J;
- Hoffmann, Karin G;
- Hughes, Miranda
- et al.
Published Web Location
http://www.jnccn.org/content/12/12/1671.fullAbstract
These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on "Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.